NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $62.89 +0.23 (+0.37 %) (As of 07/16/2018 06:38 AM ET)Previous Close$62.66Today's Range$62.25 - $63.0452-Week Range$52.83 - $66.41Volume7.35 million shsAverage Volume9.58 million shsMarket Capitalization$169.56 billionP/E Ratio15.80Dividend Yield3.05%Beta0.77 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., IO Biotech, and Premier Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Receive MRK News and Ratings via Email Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNYSE:MRK CUSIP58933Y10 Webwww.merck.com Phone908-740-4000 Debt Debt-to-Equity Ratio0.63 Current Ratio1.42 Quick Ratio1.10 Price-To-Earnings Trailing P/E Ratio15.80 Forward P/E Ratio14.94 P/E Growth2.27 Sales & Book Value Annual Sales$40.12 billion Price / Sales4.23 Cash Flow$5.7173 per share Price / Cash11.00 Book Value$12.69 per share Price / Book4.96 Profitability EPS (Most Recent Fiscal Year)$3.98 Net Income$2.39 billion Net Margins4.31% Return on Equity30.93% Return on Assets12.66% Miscellaneous Employees69,000 Outstanding Shares2,696,190,000Market Cap$169,563.39 Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions What is Merck & Co., Inc.'s stock symbol? Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK." How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.? Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Stockholders of record on Friday, June 15th will be given a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 annualized dividend and a dividend yield of 3.05%. The ex-dividend date is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History. How will Merck & Co., Inc.'s stock buyback program work? Merck & Co., Inc. announced that its board has authorized a stock buyback plan on Saturday, December 2nd 2017, which allows the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board of directors believes its stock is undervalued. How were Merck & Co., Inc.'s earnings last quarter? Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.05. The business had revenue of $10.04 billion for the quarter, compared to analysts' expectations of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. Merck & Co., Inc.'s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. View Merck & Co., Inc.'s Earnings History. When is Merck & Co., Inc.'s next earnings date? Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc.. What guidance has Merck & Co., Inc. issued on next quarter's earnings? Merck & Co., Inc. updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion. What price target have analysts set for MRK? 18 brokers have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $58.83 to $72.00. On average, they expect Merck & Co., Inc.'s share price to reach $66.0519 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View Analyst Ratings for Merck & Co., Inc.. What is the consensus analysts' recommendation for Merck & Co., Inc.? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting Merck & Co., Inc.? Merck & Co., Inc. saw a decrease in short interest in June. As of June 29th, there was short interest totalling 17,153,866 shares, a decrease of 21.6% from the June 15th total of 21,867,505 shares. Based on an average trading volume of 11,109,077 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.6% of the shares of the stock are sold short. View Merck & Co., Inc.'s Current Options Chain. Who are some of Merck & Co., Inc.'s key competitors? Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG). Who are Merck & Co., Inc.'s key executives? Merck & Co., Inc.'s management team includes the folowing people: Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 54) Has Merck & Co., Inc. been receiving favorable news coverage? Press coverage about MRK stock has trended somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co., Inc. earned a coverage optimism score of 0.12 on Accern's scale. They also assigned media headlines about the company an impact score of 46.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are Merck & Co., Inc.'s major shareholders? Merck & Co., Inc.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.29%), Swedbank (0.15%), NN Investment Partners Holdings N.V. (0.08%), Manning & Napier Group LLC (0.07%), Gateway Investment Advisers LLC (0.05%) and Hexavest Inc. (0.05%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc.. Which major investors are selling Merck & Co., Inc. stock? MRK stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Manning & Napier Group LLC, Radnor Capital Management LLC, Clinton Group Inc., Fulton Bank N.A., Fjarde AP Fonden Fourth Swedish National Pension Fund, Swedbank and Lodestar Investment Counsel LLC IL. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc.. Which major investors are buying Merck & Co., Inc. stock? MRK stock was purchased by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, LGT Capital Partners LTD., DnB Asset Management AS, Handelsbanken Fonder AB, Gofen & Glossberg LLC IL, Fisher Asset Management LLC, Neville Rodie & Shaw Inc. and Chesley Taft & Associates LLC. View Insider Buying and Selling for Merck & Co., Inc.. How do I buy shares of Merck & Co., Inc.? Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Merck & Co., Inc.'s stock price today? One share of MRK stock can currently be purchased for approximately $62.89. How big of a company is Merck & Co., Inc.? Merck & Co., Inc. has a market capitalization of $169.56 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe. How can I contact Merck & Co., Inc.? Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected] MarketBeat Community Rating for Merck & Co., Inc. (NYSE MRK)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 624 (Vote Outperform)Underperform Votes: 653 (Vote Underperform)Total Votes: 1,277MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Do closed-end mutual funds pay dividends?